Recent Advances in Chemotherapy of Gastric Cancer.
- Author:
Se Hoon PARK
1
;
Soon Il LEE
Author Information
1. Division of Hematology-Oncology, Department of Internal Medicine, Sungkyunkwan University Samsung Medical Center, Seoul, Korea. hematoma@skku.edu
- Publication Type:Review
- Keywords:
Stomach neoplasm;
Chemotherapy
- MeSH:
Biology;
Camptothecin;
Chemoradiotherapy;
Cisplatin;
Humans;
Standard of Care;
Stomach Neoplasms;
Taxoids
- From:Korean Journal of Medicine
2012;82(4):417-426
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Surgery is the best and the only treatment modality for cure if a patient has resectable gastric cancer. The outcome can be improved by a strategy of perioperative (neoadjuvant or adjuvant) chemotherapy or chemoradiotherapy. Whereas, advanced gastric cancer is treated primarily with chemotherapy; however, no chemotherapy regimen has been considered a standard. First-line chemotherapy generally includes fluoropyrimidine and cisplatin, sometimes with the addition of a third drug (epirubicin or docetaxel). In second-line setting, chemotherapy with single-agent irinotecan or docetaxel has emerged as a new standard of care. With improved understanding of the biology of gastric cancer and the identification of key signaling pathways, a number of promising molecularly-targeted agents have been studied that broaden the therapeutic options in the future. Regardless of the extent of disease or treatment modality, a multidisciplinary team approach is always desired since it can provide best treatment options for the patients.
